Lexicon Pharmaceuticals Q3 GAAP EPS $(0.21), Inline, Sales $162.00K Miss $2.06M Estimate. Cash and Investments Of $218.4M
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals reported Q3 GAAP EPS of $(0.21), in line with analyst consensus. However, the company's sales of $162.00K missed the estimate of $2.06M by 92.14%. This represents a 61.54% decrease in losses from the same period last year and a 315.38% increase in sales from the same period last year. The company's cash and investments stand at $218.4M.
November 08, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Lexicon Pharmaceuticals reported Q3 earnings in line with estimates but missed sales estimates significantly. This could potentially impact the company's stock negatively in the short term.
Lexicon Pharmaceuticals reported Q3 earnings that met analyst expectations, but the company's sales fell significantly short of estimates. This could lead to a negative sentiment among investors, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100